CAJ | 학술논문

目的评估吉西他滨联合顺铂治疗晚期非小细胞肺癌(NSCLC)的近期疗效和安全性.方法对35例晚期NSCLC患者采用吉西他滨1000mg/m~2,静滴,第1、8天;顺铂25 mg/m~2,静滴,第1～3天.28 d为1个周期,2个周期后进行一次疗效评价.结果 35例患者中完全缓解(CR)0例,部分缓解(PR)14例,稳定(SD)16例,进展(PD)5例,总有效率(CR+PR)为40.0%.初治组有效率为52.2%,显著高于复治组的16.7%(P<0.05).中位疾病进展时间(TTP)6个月.主要毒副作用是骨髓抑制和胃肠道反应.结论 GP方案对晚期NSCLC疗效较好,毒副反应轻,是晚期NSCLC特别是初治者的有效治疗方案.
목적 평고길서타빈연합순박치료만기비소세포폐암(NSCLC)적근기료효화안전성.방법 대35례만기NSCLC환자채용길서타빈1000mg/m~2,정적,제1、8천;순박25 mg/m~2,정적,제1～3천.28 d위1개주기,2개주기후진행일차료효평개.결과 35례환자중완전완해(CR)0례,부분완해(PR)14례,은정(SD)16례,진전(PD)5례,총유효솔(CR+PR)위40.0%.초치조유효솔위52.2%,현저고우복치조적16.7%(P<0.05).중위질병진전시간(TTP)6개월.주요독부작용시골수억제화위장도반응.결론 GP방안대만기NSCLC료효교호,독부반응경,시만기NSCLC특별시초치자적유효치료방안.
Objective To investigate the efficacy and toxicities of gemcitabine and cisplatin as a chemother-apy regimen for patients with advanced non-small cell lung cancer (NSCLC). Methods Thirty-five patients with NSCLC were enrolled in this study. C, emeitabine was given on day 1 and 8 at a dose of 1000 mg/m~2 and cisplatin at a dose of 25 mg/m~2 on day 1 to 3. The chemotherapy was repeated every 28 days, after 2 cycles for evaluating response. Results Complete response (CR), partial response (PR) ,stable disease (SD) and progressive disease (PD) were observed in 0,14,16 and 5 cases, respectively, with a response rate (RR) of 40. 0%. The RR in initial treatment group was found more than that in the retreatment group (52. 2% vs 16.7% ,P<0. 05).The main toxicities were tol-erable, which included myelosuppression, nausea, vomiting, and liver damage. Conclusion Gemcitabine combined with cisplatin is effective and safe in the treatment of NSCLC, especially in the initial treatment patients.